Cart
sales@molnova.com
Tulisokibart
CAS No. 2648504-55-4
Tulisokibart( —— )
Catalog No. M37264 CAS No. 2648504-55-4
Tulisokibart (PRA023) is a humanized anti-TNFSF15 monoclonal antibody used to study colon cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 613 | In Stock |
|
| 10MG | 938 | In Stock |
|
| 25MG | 1454 | In Stock |
|
| 50MG | 1841 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTulisokibart
-
NoteResearch use only, not for human use.
-
Brief DescriptionTulisokibart (PRA023) is a humanized anti-TNFSF15 monoclonal antibody used to study colon cancer.
-
DescriptionTulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody targeting to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetTNF
-
RecptorTNF
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2648504-55-4
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Feagan B G, Sands B, Siegel C A, et al. DOP87 The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn’s Disease: Phase 2a APOLLO-CD Study Results[J]. Journal of Crohn's and Colitis, 2023, 17(Supplement_1): i162-i164.
molnova catalog
related products
-
Conatumumab
Conatumumab (AMG 655) is a monoclonal agonist antibody targeting human death receptor 5 [DR5, TRAILR2] with a dissociation constant (Kd) of 1 nM for long DR5 and 0.8 nM for short DR5.
-
Physcion 8-O-β-D-glu...
Physcion 8-O-β-D-glucopyranoside has anti-inflammatory and anti-cancer activities. Physcion 8-O-β-D-glucopyranoside can be used in studies about common malignancy cancer.
-
Trilobatin
Trilobatin has anti-oxidant effect can increase superoxide dismutase (SOD) activity.Trilobatin has anti-inflammatory effect it potentially inhibits the lipopolysaccharide (LPS)-induced inflammatory response by suppressing the NF-κB signaling pathway.
